Houston entrepreneur pivots from DNA dating to a compatibility program for couples

The science of love

Brittany Barreto has expanded her DNA dating technology to a compatibility company named We Have Chemistry. Courtesy of WeHaveChemistry

As Brittany Barreto was developing and promoting her DNA-based dating app, Pheramor, that can establish compatibility in prospective couples using a certain string of genetics, she made some couples very jealous. While not single, they wanted to know the compatibility they have with their partner.

"For every single we connected with through Pheramor, there were at least three couples that wanted to complete the DNA swab to find out their compatibility," she says in a news release.

Now, Barreto and her team, which now includes acclaimed relationship expert Laura Berman, have developed WeHaveChemistry, a series of tests and DNA analysis that can give couples a look at their compatibility. And, WeHaveChemistry has taken it a step further to include more than just DNA in the report.

"The team is very excited about WeHaveChemistry," says Barreto in the release. "We've done our research and carefully crafted two reports: the socioemotional analysis and the DNA report. All couples will receive both reports to analyze their physical and emotional chemistry—which we refer to as their 'Love Alchemy."

The results aren't categorized as good or bad, and there's no score determined for couples — the findings are meant to be used to enhance the relationship and as a guide for navigating the trials and tribulations that often come with monogamy.

"The most important way for couples to ensure that their relationship stays strong is to both play to their strengths and to be honest and curious about their areas for growth," says Berman in the release. "We all have areas where we need to stretch a little, both as partners and as people, and couples can apply the findings of the SEA to their relationships and begin growing right away. In addition, the SEA identifies where we are strongest, what we should celebrate and honor, and the areas which we can rely on as a firm foundation when times get tough."

The process goes as follows:

  • Couples complete the DNA kit.
  • Each person takes the socioemotional analysis quiz, which analyzes emotional intimacy, physical connection, purpose, and future vision. The quiz will identify the person's strengths.
  • Each person receive their DNA report, which assesses sexual chemistry based on genetics.
  • The two aspects — the DNA report and the quiz results — are combined to predict and guide chemistry.

The way genetics affects attraction is completely subconscious and instinctual, dating back to primitive times.

"The science behind attraction based on your DNA is that people are attracted to one another when their immune systems are different — opposites attract is biologically true," Barreto says in a previous InnovationMap article. "When we were cavewomen and cavemen, we didn't know who was our uncle and who was our cousin, so we used our nose to figure out who is genetically diverse compared to us. If you're genetically diverse, then you're probably not my relative, and therefore we'd have healthier children."

Of course, nowadays, there are many more factors that go into compatibility and both Pheramor and WeHaveChemistry have included that in their assessments.

Swabbing for love

Courtesy of WeHaveChemistry

The DNA kit has swabs and information for two people and is sent through the mail.




Brittany Barreto wants to expand her DNA dating technology to a B-to-B model and compatibility test — all under a new company called X&Y Technologies. Karla Martin/Pheramor

Houston DNA-based dating app expands brand and plans new ways to use its technology

Love as a science

For over two years, Brittany Barreto has been playing matchmaker with her DNA-based dating app, Pheramor, but now she's ready to take it to the next level.

Pheramor, which sequences users' DNA and datamines their social media activity to determine compatibility, is transforming into becoming a product of a newly formed company called X&Y Technologies. The company, Barreto says, will have multiple products, all relating to using that same DNA technology Pheramor has perfected.

Among the first three products X&Y is working to create is a B-to-B software-as-a-service company, where established dating companies can employ Pheramor's technology for its existing app and customers. Barreto says she has two letters of intent for the B-to-B model, one of which is a dating app with 160,000 users.

Barreto unveiled the new company at The Cannon's female entrepreneur pitch night on January 24, but expanding her technology's reach has been on her mind for a while. She cited major dating companies that have their eyes on DNA dating, but haven't yet figured out the infrastructure. That, she says, is where X&Y's SaaS model comes in.

"Our traction with the dating app was a fantastic way to prove that we are the thought leaders, we have the infrastructure, and we have the algorithm and we've proven that the market is ready to buy a DNA kit to find love," she says in her pitch.

In addition, X&Y will have a compatibility test for couples wishing to learn of their own DNA-based compatibility. The tool, called We Have Chemistry, is getting ready to launch and already has preorders coming in.

"Pheramor's test is really the gold standard and industry leader in this test," she says, explaining how Pheramor's technology can be used by these existing dating apps.

She talked about how this is the time for DNA tests — from 23andme to Pheramor — and how it's not weird to send your spit in the mail. As Barreto says in her pitch, there's so much more potential for uses of the technology in what's called contextualized genetics.

"I know that my technology is way bigger than just this one market," Barreto says. "I believe the future of product is about combining the big data of genomics and DNA with the big data of your digital footprint. Nobody has ever combined your Facebook data with your DNA to figure out what's the best diet, exercise or work environment for you."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings